26. März 2018

Servier and GeNeuro announced today positive results

Servier and GeNeuro announced today positive results at 12 months from the CHANGE-MS Phase 2 study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS)

PDF icon Read more